S-Space

Browse

Subject

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 40 of 44

Issue Date	Title / Author(s) / Citation	File
2008-03	Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells Kim, Hwang-Phill; Han, Sae-Won; Kim, Sung-Hak; Im, Seock-Ah; Oh, Do-Youn; Bang, Yung-Jue; Kim, Tae-You Molecular Cancer Therapeutics, Vol.7 No.3, pp.607-615	DOI
2008-07	Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment Han, Sae-Won; Kim, Hwang-Phill; Jeon, Yoon Kyung; Oh, Do-Youn; Lee, Se-Hoon; Kim, Dong-Wan; Im, Seock-Ah; Chung, Doo Hyun; Heo, Dae Seog; Bang, Yung-Jue; Kim, Tae-You Lung Cancer, Vol.61 No.1, pp.30-34	DOI
2009-01	Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer Han, S-W; Oh, D-Y; Im, S-A; Park, S. R.; Lee, K-W; Song, H. S.; Lee, N-S; Lee, K. H.; Choi, I. S.; Lee, M. H.; Kim, M. A.; Kim, W. H.; Bang, Y-J; Kim, T-Y British Journal of Cancer, Vol.100 No.2, pp.298-304	DOI
2009-05	Involvement of NF-κB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein Kim, Su-Hyeong; Oh, Jung-Min; No, Jae-Hong; Bang, Yung-Jue; Juhnn, Yong-Sung; Song, Yong-Sang Carcinogenesis, Vol.30 No.5, pp.753-757	DOI
2010-03	An Adenoviral Vaccine Encoding Full-Length Inactivated Human Her2 Exhibits Potent Immunogenicty and Enhanced Therapeutic Efficacy without Oncogenicity Hartman, Zachary C.; Wei, Junping; Osada, Takuya; Glass, Oliver; Lei, Gangjun; Yang, Xiao-Yi; Peplinski, Sharon; Kim, Dong-Wan; Xia, Wenle; Spector, Neil; Marks, Jeffrey; Barry, William; Hobeika, Amy; Devi, Gayathri; Amalfitano, Andrea; Morse, Michael A.; Lyerly, H. Kim; Clay, Timothy M. Clinical Cancer Research, Vol.16 No.5, pp.1466-1477	DOI
2011-03	Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer Nam, Hyun-Jin; Kim, Hwang-Phill; Yoon, Young-Kwang; Hur, Hyung-Seok; Song, Sang-Hyun; Kim, Maeng-Sup; Lee, Gwan-Sun; Han, Sae-Won; Im, Seock-Ah; Kim, Tae-You; Oh, Do-Youn; Bang, Yung-Jue Cancer Letters, Vol.302 No.2, pp.155-165	DOI
2011-04	EGFR Gene Copy Number Gain is Related to High Tumor SUV and Frequent Relapse after Adjuvant Chemotherapy in Resected Lung Adenocarcinoma Koh, Youngil; Jang, Bogun; Jeon, Yoon Kyung; Kim, Tae Min; Lee, Se-Hoon; Kim, Dong-Wan; Chung, Doo Hyun; Kim, Young Tae; Kim, Young Whan; Heo, Dae Seog Japanese Journal of Clinical Oncology, Vol.41 No.4, pp.548-554	DOI
2011-08	Detection of ALK gene rearrangement in non-small cell lung cancer: A comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression Kim, Hyojin; Yoo, Seol-Bong; Choe, Ji-Young; Paik, Jin Ho; Xu, Xianhua; Nitta, Hiroaki; Zhang, Wenjun; Grogan, Thomas M.; Lee, Choon-Taek; Jheon, Sanghoon; Chung, Jin-Haeng Journal of Thoracic Oncology, Vol.6 No.8, pp.1359-1366	DOI
2011-10	Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer Park, Jin Hyun; Han, Sae-Won; Oh, Do-Youn; Im, Seock-Ah; Jeong, Seung-Yong; Park, Kyu Joo; Kim, Tae-You; Bang, Yung-Jue; Park, Jae-Gahb Cancer Chemotherapy and Pharmacology, Vol.68 No.4, pp.1045-1055	DOI
2011-11	Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma Kim, Min A.; Lee, Hyuk-Joon; Yang, Han-Kwang; Bang, Yung-Jue; Kim, Woo Ho Histopathology, Vol.59 No.5, pp.822-831	DOI
2011-12	MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib Lennerz, Jochen K.; Kwak, Eunice L.; Ackerman, Allison; Michael, Michael; Fox, Stephen B.; Bergethon, Kristin; Lauwers, Gregory Y.; Christensen, James G.; Wilner, Keith D.; Haber, Daniel A.; Salgia, Ravi; Bang, Yung-Jue; Clark, Jeffrey W.; Solomon, Benjamin J.; Iafrate, A. John Journal of Clinical Oncology, Vol.29 No.36, pp.4803-4810	DOI
2012-07	Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers Yun, Jiyeon; Song, Sang-Hyun; Park, Jinah; Kim, Hwang-Phill; Yoon, Young-Kwang; Lee, Kyung-Hun; Han, Sae-Won; Oh, Do-Youn; Im, Seock-Ah; Bang, Yung-Jue; Kim, Tae-You Laboratory Investigation, Vol.92 No.7, pp.1033-1044	DOI
2012-07	MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome Lee, H. E.; Kim, M. A.; Lee, H. S.; Jung, E-J; Yang, H-K; Lee, B. L.; Bang, Y-J; Kim, W. H. British Journal of Cancer, Vol.107 No.2, pp.325-333	DOI
2012-08	EGFR mutations as a predictive marker of cytotoxic chemotherapy Park, Jin Hyun; Lee, Se-Hoon; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Yang, Seok-Chul; Kim, Young Whan; Heo, Dae Seog Lung Cancer, Vol.77 No.2, pp.433-437	DOI
2012-09	Advances in the Management of HER2-positive Advanced Gastric and Gastroesophageal Junction Cancer Bang, Yung-Jue Journal of Clinical Gastroenterology, Vol.46 No.8, pp.637-648	DOI
2013-01	Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer Nam, Hyun-Jin; Im, Seock-Ah; Oh, Do-Youn; Elvin, Paul; Kim, Hwang-Phill; Yoon, Young-Kwang; Min, Ahrum; Song, Sang-Hyun; Han, Sae-Won; Kim, Tae-You; Bang, Yung-Jue Molecular Cancer Therapeutics, Vol.12 No.1, pp.16-26	DOI
2013-01	KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: A pooled analysis of 2 phase II trials Kim, Sun Young; Shim, Eun Kyung; Yeo, Hyun Yang; Baek, Ji Yeon; Hong, Yong Sang; Kim, Dae Yong; Kim, Tae Won; Kim, Jee Hyun; Im, Seock-Ah; Jung, Kyung Hae; Chang, Hee Jin International Journal of Radiation Oncology Biology Physics, Vol.85 No.1, pp.201-207	DOI
2014-09	AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William Cancer Discovery, Vol.4 No.9, pp.1046-1061	DOI
2014-10	Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non-Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib A Phase I/II Trial Park, Keunchil; Cho, Byoung C.; Kim, Dong-Wan; Ahn, Myung-Ju; Lee, Sang-Yoon; Gernhardt, Diana; Taylor, Ian; Campbell, Alicyn K.; Zhang, Hui; Giri, Nagdeep; Letrent, Stephen P.; O'Connell, Joseph; Heo, Dae S. Journal of Thoracic Oncology, Vol.9 No.10, pp.1523-1531	DOI
2015-01	Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer Lee, H. J.; Seo, A. N.; Kim, E. J.; Jang, M. H.; Kim, Y. J.; Kim, J. H.; Kim, S. -W.; Ryu, H. S.; Park, I. A.; Im, S. -A.; Gong, G.; Jung, K. H.; Kim, H. J.; Park, S. Y. British Journal of Cancer, Vol.112 No.1, pp.103-111	DOI
2015-05	A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) Blumenschein, G. R., Jr.; Smit, E. F.; Planchard, D.; Kim, D. -W.; Cadranel, J.; De Pas, T.; Dunphy, F.; Udud, K.; Ahn, M. -J.; Hanna, N. H.; Kim, J. -H.; Mazieres, J.; Kim, S. -W.; Baas, P.; Rappold, E.; Redhu, S.; Puski, A.; Wu, F. S.; Jaenne, P. A. Annals of Oncology, Vol.26 No.5, pp.894-901	DOI
2015-08	Total lesion glycolysis in positron emission tomography can predict gefitinib outcomes in non-small-cell lung cancer with activating EGFR mutation Keam, Bhumsuk; Lee, Soo Jin; Kim, Tae Min; Paeng, Jin Chul; Lee, Se-Hoon; Kim, Dong-Wan; Jeon, Yoon Kyung; Chung, Doo Hyun; Kang, Keon Wook; Chung, June-Key; Heo, Dae Seog Journal of Thoracic Oncology, Vol.10 No.8, pp.1189-1194	DOI
2015-09	Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status Koh, Jaemoon; Go, Heounjeong; Keam, Bhumsuk; Kim, Moon-Young; Nam, Soo Jeong; Kim, Tae Min; Lee, Se-Hoon; Min, Hye Sook; Kim, Young Tae; Kim, Dong-Wan; Jeon, Yoon Kyung; Chung, Doo Hyun Modern Pathology, Vol.28 No.9, pp.1154-1166	DOI
2015-10	A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer Lee, Keun-Wook; Koh, Youngil; Kim, Sung-Bae; Shin, Sang-Won; Kang, Jin-Hyoung; Wu, Hong-Gyun; Sung, Myung-Whun; Keam, Bhumsuk; Kim, Dong-Wan; Kim, Tae Min; Kim, Kwang Hyun; Kwon, Tack-Kyun; Hah, J. Hun; Kim, In-Ah; Ahn, Soon-Hyun; Yoon, Dok Hyun; Lee, Sang-Wook; Kim, Sang Yoon; Nam, Soon Yuhl; Jung, Kwang-Yoon; Baek, Seung-Kuk; Hong, Sook Hee; Lee, Se-Hoon; Heo, Dae Seog Oncologist, Vol.20 No.10, pp.1119-1120	DOI
2016-01	Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer Kim, Ji-Won; Kim, Debora K.; Min, Ahrum; Lee, Kyung-Hun; Nam, Hyun-Jin; Kim, Jee Hyun; Kim, Jin-Soo; Kim, Tae-Yong; Im, Seock-Ah; Park, In Ae Journal of Cancer Research and Clinical Oncology, Vol.142 No.1, pp.157-165	DOI
2016-02	Pertuzumab in gastrointestinal cancer Oh, Do-Youn; Bang, Yung-Jue Expert Opinion on Biological Therapy, Vol.16 No.2, pp.243-253	DOI
2016-03	A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806) Lim, Sun Min; Cho, Byoung Chul; Kim, Sang-We; Kang, Seok Yun; Heo, Dae Seog; Kim, Heung Tae; Lee, Dae Ho; Kim, Dong-Wan; Jung, Minkyu; Choi, Jin-Hyuk; Shim, Hyo Sup; Choi, Jong Rak; Kim, Joo-Hang Lung Cancer, Vol.93, pp.1-8	DOI
2016-07	Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer Han, Jae Joon; Kim, Dong-Wan; Koh, Jaemoon; Keam, Bhumsuk; Kim, Tae Min; Jeon, Yoon Kyung; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog Clinical Lung Cancer, Vol.17 No.4, pp.263-270	DOI
2016-11	The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas Cho, Jaeyoung; Choi, Sun Mi; Lee, Jinwoo; Lee, Chang-Hoon; Lee, Sang-Min; Yim, Jae-Joon; Chung, Doo Hyun; Yoo, Chul-Gyu; Kim, Young Whan; Han, Sung Koo; Park, Young Sik PLoS ONE, Vol.11 No.11, p. e0166821	DOI
2016-12	Suppression of osteopontin inhibits chemically induced hepatic carcinogenesis by induction of apoptosis in mice Lee, Su-Hyung; Park, Jun-Won; Woo, Sang-Ho; Go, Du-Min; Kwon, Hyo-Jung; Jang, Ja-June; Kim, Dae-Yong Oncotarget, Vol.7 No.52, pp.87219-87231	DOI
2017-01	HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-O13/LOGiC Trial of Lapatinib Press, Michael F.; Ellis, Catherine E.; Gagnon, Robert C.; Grob, Tobias J.; Buyse, Marc; Villalobos, Ivonne; Liang, Zhiyong; Wu, Shafei; Bang, Yung-Jue; Qin, Shu-Kui; Chung, Hyun Cheol; Xu, Jianming; Park, Joon Oh; Jeziorski, Krzysztof; Afenjar, Karen; Ma, Yanling; Estrada, Monica C.; Robinson, Douglas M.; Scherer, Stefan J.; Sauter, Guido; Hecht, J. Randolph; Slamon, Dennis J. Molecular Cancer Therapeutics, Vol.16 No.1, pp.228-238	DOI
2017-02	Proportion and clinical features of never-smokers with non-small cell lung cancer Cho, Jaeyoung; Choi, Sun Mi; Lee, Jinwoo; Lee, Chang-Hoon; Lee, Sang-Min; Kim, Dong-Wan; Yim, Jae-Joon; Kim, Young Tae; Yoo, Chul-Gyu; Kim, Young Whan; Han, Sung Koo; Park, Young Sik Chinese Journal of Cancer, Vol.36 No.1, p. 20	DOI
2017-02	The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis Chan, David L.; Sjoquist, Katrin M.; Goldstein, David; Price, Timothy J.; Martin, Andrew J.; Bang, Yung-Jue; Kang, Yoon-Koo; Pavlakis, Nick PLoS ONE, Vol.12 No.2, p. e0172307	DOI
2017-03	Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer Shin, Junghoon; Keam, Bhumsuk; Kim, Miso; Park, Young Sik; Kim, Tae Min; Kim, Dong-Wan; Kim, Young Whan; Heo, Dae Seog Journal of Thoracic Oncology, Vol.12 No.3, pp.520-528	DOI
2017-04	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component Yang, James Chih-Hsin; Ahn, Myung-Ju; Kim, Dong-Wan; Ramalingam, Suresh S.; Sequist, Lecia V.; Su, Wu-Chou; Kim, Sang-We; Kim, Joo-Hang; Planchard, David; Felip, Enriqueta; Blackhall, Fiona; Haggstrom, Daniel; Yoh, Kiyotaka; Novello, Silvia; Gold, Kathryn; Hirashima, Tomonori; Lin, Chia-Chi; Mann, Helen; Cantarini, Mireille; Ghiorghiu, Serban; Janne, Pasi A. Journal of Clinical Oncology, Vol.35 No.12, pp.1288-1296	DOI
2018-12	A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial Park, Yeon Hee; Lee, Kyung-Hun; Sohn, Joo Hyuk; Lee, Keun Seok; Jung, Kyung Hae; Kim, Jee-Hyun; Lee, Ki Hyeong; Ahn, Jin Seok; Kim, Tae-Yong; Kim, Gun Min; Park, In Hae; Kim, Sung-Bae; Kim, Se Hyun; Han, Hye Sook; Im, Young-Hyuck; Ahn, Jin-Hee; Kim, Jung-Yong; Kang, Jahoon; Im, Seock-Ah International Journal of Cancer, Vol.143 No.12, pp.3240-3247	DOI
2019-01	The risk of herpes zoster in patients with non-small cell lung cancer according to chemotherapy regimens: Tyrosine kinase inhibitors versus cytotoxic chemotherapy Choi, Ji Young; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Jo, Seong Jin Cancer Research and Treatment, Vol.51 No.1, pp.169-177	DOI
2019-02	Bispecific anti-mPDGFR beta x cotinine scFv-C-kappa-scFv fusion protein and cotinine-duocarmycin can form antibody-drug conjugate-like complexes that exert cytotoxicity against mPDGFR beta expressing cells Kim, Soohyun; Kim, Hyori; Jo, Dong Hyun; Kim, Jeong Hun; Kim, Su Ree; Kang, Dongmin; Hwang, Dobeen; Chung, Junho Methods, Vol.154, pp.125-135	DOI
2019-07	Acquired resistance of MET-amplified non-small cell lung cancer cells to the MET inhibitor capmatinib Kim, Seulki; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Alm, Yong-Oon; Keam, Bhumsuk; Heo, Dae Seog Cancer Research and Treatment, Vol.51 No.3, pp.951-962	DOI
2019-09	GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer Park, Ji Eun; Jin, Mei Hua; Hur, Minkyu; Nam, Ah-Rong; Bang, Ju-Hee; Won, Jonghwa; Oh, Do-Youn; Bang, Yung-Jue Gastric Cancer, Vol.22 No.5, pp.932-940	DOI

1 2